ACM
ATRA icon

Aquatic Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Aquatic Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-332
Closed -$27K – 1252
2022
Q4 		$27K Sell
332
-1,532
-82% -$160K ﹤0.01% 1118
2022
Q3 		$176K Buy
+1,864
New +$209K 0.02% 635

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aquatic Capital Management's ATRA Position: Q1 2023 in Review

Aquatic Capital Management sold out of Atara Biotherapeutics (ATRA) in Q1 2023, closing a stake of 332 shares — an estimated $27K sold.

Aquatic Capital Management first reported a position in ATRA in Q3 2022 and held it in 2 quarters. The position peaked at $176K in Q3 2022. 125 funds tracked by Wall St. Rank hold ATRA as of Q1 2023.

  • Aquatic Capital Management reported no remaining Atara Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 332 Atara Biotherapeutics shares in Q1 2023, an estimated $27K.
  • Aquatic Capital Management first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 2 quarters.
  • Aquatic Capital Management's Atara Biotherapeutics position peaked at $176K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2023.

Based on Aquatic Capital Management's 13F filing for Q1 2023, filed 15 May 2023.